Wednesday, June 25, 2025 7:34:15 PM
Iron Mike, it may be clear that when Sawston is built out it will be able to supply all UK demands and perhaps even all of Europe, but it's clear that the company is looking for additional sites elsewhere in the world, they've said so in their financials.
I believe it's clear they're not looking for tiny cleanrooms to manually make DCVax-L, they're looking for larger cleanrooms with adequate capacity to take multiple EDEN units that also have the capability of properly handling all aspects of making, storing and distributing the vaccine.
It's my believe that such capability exists in many places throughout the world. In some cases it may be for just a few EDEN units, in other places hundreds of even thousands of units. The point is that multiple such facilities will work until such time as the supply is completely in line with the demand.
I don't know how many brain surgeries are done in LA in a year, but I don't believe that it's more than a few hundred a year. I would suspect that UCLA, or City of Hope, or others in LA could handle perhaps 10 units, each capable of 50 batches of vaccine, or 500 batches a year. Probably all that's needed for the Greater LA area for brain cancers alone. Of course, if the vaccine is labeled tumor agnostic, then the numbers would need to increase dramatically. I don't believe it would be a problem within all the fine medical facilities located in the greater LA area.
I wouldn't be surprised to find that nearly every facility equipped to do brain surgery may have all the capabilities needed to make the vaccine.
Gary
I believe it's clear they're not looking for tiny cleanrooms to manually make DCVax-L, they're looking for larger cleanrooms with adequate capacity to take multiple EDEN units that also have the capability of properly handling all aspects of making, storing and distributing the vaccine.
It's my believe that such capability exists in many places throughout the world. In some cases it may be for just a few EDEN units, in other places hundreds of even thousands of units. The point is that multiple such facilities will work until such time as the supply is completely in line with the demand.
I don't know how many brain surgeries are done in LA in a year, but I don't believe that it's more than a few hundred a year. I would suspect that UCLA, or City of Hope, or others in LA could handle perhaps 10 units, each capable of 50 batches of vaccine, or 500 batches a year. Probably all that's needed for the Greater LA area for brain cancers alone. Of course, if the vaccine is labeled tumor agnostic, then the numbers would need to increase dramatically. I don't believe it would be a problem within all the fine medical facilities located in the greater LA area.
I wouldn't be surprised to find that nearly every facility equipped to do brain surgery may have all the capabilities needed to make the vaccine.
Gary
Bullish
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
